XFOR completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed purchaser for $105 million and it has drawn an additional tranche of $20 million under its existing loan facility with Hercules Capital

$X4 Pharmaceuticals(XFOR)$ 价值连城的优先审评券。